📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Optimised versus standard dosing of vancomycin in infants with Gram-positive sepsis (NeoVanc): a multicentre, randomised, open-label, phase 2b, non-inferiority trial. (2022)

First Author: Hill LF

Attributed to: Method - Design funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s2352-4642(21)00305-9

PubMed Identifier: 34843669

Publication URI: http://europepmc.org/abstract/MED/34843669

Type: Journal Article/Review

Volume: 6

Parent Publication: The Lancet. Child & adolescent health

Issue: 1

ISSN: 2352-4642